Haystack Oncology

Introducing Haystack Oncology, a company at the forefront of revolutionizing cancer diagnostics.

Haystack Oncology harnesses over two decades of innovation in liquid biopsy technology to empower precision oncology, focusing on early detection and monitoring of minimal residual disease (MRD) to enhance patient outcomes.

Our founding team comprises industry pioneers and experienced leaders in oncology diagnostics, bringing a wealth of knowledge and proven success in cancer genomics.

With approximately 1.6 million US patients diagnosed with solid tumors annually and a $13-15 billion total addressable market, our MRD testing has the potential to significantly impact early cancer treatment strategies and patient management.

Utilizing our patented Duo technology, Haystack MRD testing delivers unparalleled sensitivity for early detection of residual cancer, enabling personalized monitoring and informed clinical decisions throughout a patient's treatment journey.

Clinical trial results demonstrate the robust performance of our technology in enhancing treatment response monitoring and guiding therapeutic strategies, highlighting our platform's real-world impact.

Haystack is strategically positioned to commercialize our MRD testing, with planned expansion in the US and EU and a clear pathway through regulatory approval to deliver our service to patients and providers.

Join us in transforming oncology clinical practice with Haystack Oncology, where innovative technology meets precision medicine to save lives.